A phase 1, randomized, double-blind, placebo-controlled assessment of the safety, tolerability, and activity of GS-9191 ointment for the treatment of external genital and perianal warts caused by human papilloma virus infection

Trial Profile

A phase 1, randomized, double-blind, placebo-controlled assessment of the safety, tolerability, and activity of GS-9191 ointment for the treatment of external genital and perianal warts caused by human papilloma virus infection

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2009

At a glance

  • Drugs GS 9191 (Primary)
  • Indications Genital warts
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2009 Actual end date (Mar 2009) added, actual patient number (202) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top